Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

A new drug to potentially treat depression and neurodegenerative diseases, such as dementia or Parkinson’s, is being ...

Groundbreaking research reveals potential link between cytomegalovirus (CMV) and Alzheimer's disease, offering new insights ...

Both drugs work by reducing the brain amyloid levels in patients in the early stages of Alzheimer’s, and act to slow the disease. Still, they don’t stop or reverse it, while both treatments ...

Discover how dopamine’s unexpected role in breaking down harmful plaques could revolutionize Alzheimer's treatment and ...

A new study has identified polyphosphate as a likely "mystery density" within fibrils associated with Alzheimer's and other ...

Recent studies implicate the immune system and a herpes virus as potential contributors to development of disease ...

There’s intriguing news today about a technology that could improve treatment in people with Alzheimer’s. It uses sound waves ...

As the second oral therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer’s disease during the past decade, ZUNVEYL demonstrates a potentially better safety ...

Both drugs work by reducing the brain amyloid levels in patients in the early stages of Alzheimer’s, and act to slow the disease. Still, they don’t stop or reverse it, while both treatments ...

Discover the surprising link between herpes and Alzheimer's disease. Find out how the common herpes simplex virus may play a ...

(Bloomberg) -- Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for Alzheimer’s disease in 2025. Companies including Biogen Inc.